Omran Hazem, Rudolph Tanja K, Faber Lothar, Rudolph Volker, Dimitriadis Zisis
Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germany.
Medical Clinic II, Lukas-Hospital, 32257 Bünde, Germany.
J Clin Med. 2025 May 19;14(10):3546. doi: 10.3390/jcm14103546.
Risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) remains challenging, especially in high-risk cohorts. This study evaluated the predictive utility of the ESC HCM Risk Score and the additive value of myocardial fibrosis assessment via cardiac magnetic resonance (CMR) in HCM patients with implantable cardioverter-defibrillators (ICDs) for primary prevention. : A retrospective analysis was conducted on 108 HCM patients (mean age 49.4 ± 14.2 years; 30.6% female; 63.9% with LVOT obstruction) with ICDs for primary SCD prevention. The primary endpoint was a composite of all-cause mortality or appropriate ICD therapy for ventricular arrhythmia over a mean follow-up of 69.5 ± 22.8 months. ESC HCM Risk Scores, the presence of fibrosis on CMR, and clinical outcomes were analyzed using univariate and multivariate models, ROC curves, and Kaplan-Meier survival estimates. The primary endpoint occurred in 25 patients (23.1%; 3.1%/year). An ESC HCM Risk Score ≥ 4% was common (81.5%) but did not significantly predict the primary outcome (the c-statistic 0.54; = 0.08) and demonstrated low positive (25%) and high negative predictive values (85%). Severe fibrosis on CMR was significantly associated with events in univariate analysis ( = 0.04), and its inclusion improved the model's predictive accuracy (the c-statistic increased to 0.65; = 0.03). Kaplan-Meier analysis revealed worse event-free survival in patients with both elevated ESC scores and more than mild fibrosis ( = 0.028). : In this high-risk HCM cohort with ICDs, the ESC risk score showed limited predictive performance, while myocardial fibrosis on CMR added significant prognostic value. Incorporating the fibrosis assessment into future risk models may enhance SCD prediction and refine ICD decision-making in HCM. Further multicenter studies are needed to validate these findings.
肥厚型心肌病(HCM)中心脏性猝死(SCD)的风险分层仍然具有挑战性,尤其是在高危人群中。本研究评估了ESC HCM风险评分的预测效用,以及通过心脏磁共振成像(CMR)评估心肌纤维化在植入式心脏复律除颤器(ICD)一级预防的HCM患者中的附加价值。对108例植入ICD进行SCD一级预防的HCM患者进行回顾性分析。患者平均年龄49.4±14.2岁;女性占30.6%;63.9%存在左心室流出道梗阻。主要终点是在平均69.5±22.8个月的随访期内全因死亡率或ICD对室性心律失常的恰当治疗的复合终点。使用单因素和多因素模型、ROC曲线以及Kaplan-Meier生存估计分析ESC HCM风险评分、CMR上纤维化的存在情况和临床结局。25例患者(23.1%;3.1%/年)发生主要终点事件。ESC HCM风险评分≥4%很常见(81.5%),但并不能显著预测主要结局(c统计量为0.54;P = 0.08),且显示出低阳性预测值(25%)和高阴性预测值(85%)。CMR上的严重纤维化在单因素分析中与事件显著相关(P = 0.04),将其纳入模型可提高模型的预测准确性(c统计量增至0.65;P = 0.03)。Kaplan-Meier分析显示,ESC评分升高且纤维化程度超过轻度的患者无事件生存期更差(P = 0.028)。在这个植入ICD的高危HCM队列中,ESC风险评分显示出有限的预测性能,而CMR上的心肌纤维化增加了显著的预后价值。将纤维化评估纳入未来的风险模型可能会增强HCM中SCD的预测并优化ICD决策。需要进一步的多中心研究来验证这些发现。